Are Cladribine and Rituximab Enough for the Treatment of Relapsed Hairy Cell Leukemia?
نویسندگان
چکیده
منابع مشابه
Cladribine with immediate rituximab for the treatment of patients with variant hairy cell leukemia.
PURPOSE In contrast with the classic form, variant hairy cell leukemia (HCLv) responds poorly to single-agent purine analogs, expresses unmutated BRAF, has shorter overall survival, and lacks effective standard therapy. No treatment has achieved a high complete remission (CR) rate even in small series, and of 39 reported cases from six studies, overall response rate after cladribine was 44% wit...
متن کاملPhase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia.
Hairy cell leukemia (HCL) is an indolent B-cell neoplasm, strongly expressing CD20. Despite initial very high response rates following cladribine, many patients (pts) ultimately relapse. Having relapsed after prior treatment with cladribine, 24 HCL pts (21 male, 3 female) with a median age of 53.5 years were treated with rituximab at 375 mg/m2 intravenously weekly for 4 weeks. Of the pts, 3 (13...
متن کاملBendamustine and rituximab in relapsed and refractory hairy cell leukemia.
PURPOSE To determine tolerability and for the first time explore efficacy of bendamustine-rituximab (BR) in multiply relapsed/refractory hairy cell leukemia (HCL), using two different dose levels of bendamustine. EXPERIMENTAL DESIGN Patients with HCL with ≥2 prior therapies requiring treatment received rituximab 375 mg/m(2) days 1 and 15 plus bendamustine 70 (n = 6) or 90 (n = 6) mg/m(2), day...
متن کاملRituximab in relapsed or refractory hairy cell leukemia.
The purpose of this study was to investigate the efficacy and safety of the monoclonal antibody, rituximab, in relapsed or refractory hairy cell leukemia (HCL). Fifteen patients with relapsed or primary refractory HCL after nucleoside analogs received rituximab 375 mg/m2 weekly for a total of 8 planned doses. An additional 4 doses could be administered to responders who had not achieved complet...
متن کاملCancer Therapy: Clinical Cladribine with Immediate Rituximab for the Treatment of Patients with Variant Hairy Cell Leukemia
Purpose: In contrast with the classic form, variant hairy cell leukemia (HCLv) responds poorly to singleagent purine analogs, expresses unmutated BRAF, has shorter overall survival, and lacks effective standard therapy. No treatment has achieved a high complete remission (CR) rate even in small series, and of 39 reported cases from six studies, overall response rate after cladribine was 44% wit...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: International Journal of Immunotherapy and Cancer Research
سال: 2015
ISSN: 2455-8591
DOI: 10.17352/2455-8591.000002